Compare BioNano Genomics Inc (BNGO) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Palantir Technologies Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Palantir Technologies Inc trades at $172.36 (market cap $420.39B). The key difference: Palantir Technologies Inc is far larger — about 30775.3× BioNano Genomics Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PLTR | |
|---|---|---|
Market Cap | $13.66M | $420.39B |
Sector | Health | Technology |
52-Week High | $4.92 | $207.18 |
52-Week Low | $1.06 | $107.27 |
Enterprise Value | $16.26M | $411.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
PLTR trades at $170.50, down 2.68% today but maintains strong momentum with bullish moving averages and recent earnings beats. The company demonstrates exceptional financial performance with 84.8% gross margins and 49% net income margin, though valuation metrics remain elevated with P/E of 149.52. Recent news highlights conflicting institutional views with Cathie Wood selling while analysts maintain buy ratings.
Outlook remains positive with accelerating revenue growth and strong profitability, but high valuations and insider selling present risks. The consensus price target of $213.44 suggests 25% upside potential, though competition and market volatility could pressure the stock near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
